Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR)
Current guidelines favor dual anti-platelet therapy with ticagrelor 90 mg BID (T90BID) over clopidogrel 75 mg QD (C75QD) in addition to aspirin for acute coronary syndrome. However, an increased risk of ticagrelor-related adverse events prompted the evaluation of low-dose regimens. This study (NCT03...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-01-01
|
| Series: | Platelets |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09537104.2020.1732328 |
| _version_ | 1827816882021859328 |
|---|---|
| author | Jing Shi Meijiao He Wennan Wang Guangzhong Liu Haiyu Zhang Danghui Sun Jianqiang Li Hongyuan Mu Minglu Xu Chenyang Zhao Jiayu Wang Chongyang Zhang Hai Cang Shiqi Zhao Zhiren Zhang Yue Li |
| author_facet | Jing Shi Meijiao He Wennan Wang Guangzhong Liu Haiyu Zhang Danghui Sun Jianqiang Li Hongyuan Mu Minglu Xu Chenyang Zhao Jiayu Wang Chongyang Zhang Hai Cang Shiqi Zhao Zhiren Zhang Yue Li |
| author_sort | Jing Shi |
| collection | DOAJ |
| description | Current guidelines favor dual anti-platelet therapy with ticagrelor 90 mg BID (T90BID) over clopidogrel 75 mg QD (C75QD) in addition to aspirin for acute coronary syndrome. However, an increased risk of ticagrelor-related adverse events prompted the evaluation of low-dose regimens. This study (NCT03381742) retrospectively analyzed the data from 11 hospitals on 3,043 patients with coronary artery disease, who received C75QD, T90BID, ticagrelor 45 mg BID (T45BID), or ticagrelor 90 mg QD (T90QD). Compared with C75QD, both T45BID and T90QD showed significantly higher inhibition of platelet aggregation (P < .0001) and lower platelet-fibrin clot strength (P < .0001) induced by adenosine diphosphate. Furthermore, compared with T90BID, two low-dose regimens had a much lower minor bleeding rate and a significantly higher proportion of patients within the therapeutic window for P2Y12 receptor reactivity. There were no significant differences between T45BID and T90QD in the trough plasma concentrations of ticagrelor and its active metabolite. Similar efficacy and safety outcomes were observed in the propensity score-matched analysis. In conclusion, the low-dose ticagrelor regimen, either T45BID or T90QD, may provide a more attractive benefit-risk profile than C75QD or T90BID. |
| first_indexed | 2024-03-12T00:26:39Z |
| format | Article |
| id | doaj.art-de5c4dc4dc8c496383c79c8a75669210 |
| institution | Directory Open Access Journal |
| issn | 0953-7104 1369-1635 |
| language | English |
| last_indexed | 2024-03-12T00:26:39Z |
| publishDate | 2021-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Platelets |
| spelling | doaj.art-de5c4dc4dc8c496383c79c8a756692102023-09-15T10:38:07ZengTaylor & Francis GroupPlatelets0953-71041369-16352021-01-0132112012910.1080/09537104.2020.17323281732328Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR)Jing Shi0Meijiao He1Wennan Wang2Guangzhong Liu3Haiyu Zhang4Danghui Sun5Jianqiang Li6Hongyuan Mu7Minglu Xu8Chenyang Zhao9Jiayu Wang10Chongyang Zhang11Hai Cang12Shiqi Zhao13Zhiren Zhang14Yue Li15Harbin Medical UniversityHarbin Medical UniversityHarbin Medical UniversityHarbin Medical UniversityHarbin Medical UniversityHarbin Medical UniversityHarbin Medical UniversityHarbin Medical UniversityHarbin Medical UniversityHarbin Medical UniversityHarbin Medical UniversityHarbin Medical UniversityHarbin Medical UniversityHarbin Medical UniversityInstitute of Metabolic Disease, Heilongjiang Academy of Medical ScienceHarbin Medical UniversityCurrent guidelines favor dual anti-platelet therapy with ticagrelor 90 mg BID (T90BID) over clopidogrel 75 mg QD (C75QD) in addition to aspirin for acute coronary syndrome. However, an increased risk of ticagrelor-related adverse events prompted the evaluation of low-dose regimens. This study (NCT03381742) retrospectively analyzed the data from 11 hospitals on 3,043 patients with coronary artery disease, who received C75QD, T90BID, ticagrelor 45 mg BID (T45BID), or ticagrelor 90 mg QD (T90QD). Compared with C75QD, both T45BID and T90QD showed significantly higher inhibition of platelet aggregation (P < .0001) and lower platelet-fibrin clot strength (P < .0001) induced by adenosine diphosphate. Furthermore, compared with T90BID, two low-dose regimens had a much lower minor bleeding rate and a significantly higher proportion of patients within the therapeutic window for P2Y12 receptor reactivity. There were no significant differences between T45BID and T90QD in the trough plasma concentrations of ticagrelor and its active metabolite. Similar efficacy and safety outcomes were observed in the propensity score-matched analysis. In conclusion, the low-dose ticagrelor regimen, either T45BID or T90QD, may provide a more attractive benefit-risk profile than C75QD or T90BID.http://dx.doi.org/10.1080/09537104.2020.1732328bleedingclopidogrelinhibition of platelet aggregationlow-dose ticagrelor |
| spellingShingle | Jing Shi Meijiao He Wennan Wang Guangzhong Liu Haiyu Zhang Danghui Sun Jianqiang Li Hongyuan Mu Minglu Xu Chenyang Zhao Jiayu Wang Chongyang Zhang Hai Cang Shiqi Zhao Zhiren Zhang Yue Li Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR) Platelets bleeding clopidogrel inhibition of platelet aggregation low-dose ticagrelor |
| title | Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR) |
| title_full | Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR) |
| title_fullStr | Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR) |
| title_full_unstemmed | Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR) |
| title_short | Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR) |
| title_sort | efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease a retrospective multicenter study superior |
| topic | bleeding clopidogrel inhibition of platelet aggregation low-dose ticagrelor |
| url | http://dx.doi.org/10.1080/09537104.2020.1732328 |
| work_keys_str_mv | AT jingshi efficacyandsafetyofdifferentticagrelorregimensversusclopidogrelinpatientswithcoronaryarterydiseasearetrospectivemulticenterstudysuperior AT meijiaohe efficacyandsafetyofdifferentticagrelorregimensversusclopidogrelinpatientswithcoronaryarterydiseasearetrospectivemulticenterstudysuperior AT wennanwang efficacyandsafetyofdifferentticagrelorregimensversusclopidogrelinpatientswithcoronaryarterydiseasearetrospectivemulticenterstudysuperior AT guangzhongliu efficacyandsafetyofdifferentticagrelorregimensversusclopidogrelinpatientswithcoronaryarterydiseasearetrospectivemulticenterstudysuperior AT haiyuzhang efficacyandsafetyofdifferentticagrelorregimensversusclopidogrelinpatientswithcoronaryarterydiseasearetrospectivemulticenterstudysuperior AT danghuisun efficacyandsafetyofdifferentticagrelorregimensversusclopidogrelinpatientswithcoronaryarterydiseasearetrospectivemulticenterstudysuperior AT jianqiangli efficacyandsafetyofdifferentticagrelorregimensversusclopidogrelinpatientswithcoronaryarterydiseasearetrospectivemulticenterstudysuperior AT hongyuanmu efficacyandsafetyofdifferentticagrelorregimensversusclopidogrelinpatientswithcoronaryarterydiseasearetrospectivemulticenterstudysuperior AT mingluxu efficacyandsafetyofdifferentticagrelorregimensversusclopidogrelinpatientswithcoronaryarterydiseasearetrospectivemulticenterstudysuperior AT chenyangzhao efficacyandsafetyofdifferentticagrelorregimensversusclopidogrelinpatientswithcoronaryarterydiseasearetrospectivemulticenterstudysuperior AT jiayuwang efficacyandsafetyofdifferentticagrelorregimensversusclopidogrelinpatientswithcoronaryarterydiseasearetrospectivemulticenterstudysuperior AT chongyangzhang efficacyandsafetyofdifferentticagrelorregimensversusclopidogrelinpatientswithcoronaryarterydiseasearetrospectivemulticenterstudysuperior AT haicang efficacyandsafetyofdifferentticagrelorregimensversusclopidogrelinpatientswithcoronaryarterydiseasearetrospectivemulticenterstudysuperior AT shiqizhao efficacyandsafetyofdifferentticagrelorregimensversusclopidogrelinpatientswithcoronaryarterydiseasearetrospectivemulticenterstudysuperior AT zhirenzhang efficacyandsafetyofdifferentticagrelorregimensversusclopidogrelinpatientswithcoronaryarterydiseasearetrospectivemulticenterstudysuperior AT yueli efficacyandsafetyofdifferentticagrelorregimensversusclopidogrelinpatientswithcoronaryarterydiseasearetrospectivemulticenterstudysuperior |